0001209191-23-037968.txt : 20230616
0001209191-23-037968.hdr.sgml : 20230616
20230616170514
ACCESSION NUMBER: 0001209191-23-037968
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230614
FILED AS OF DATE: 20230616
DATE AS OF CHANGE: 20230616
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hineline Lawrence J.
CENTRAL INDEX KEY: 0001585697
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36274
FILM NUMBER: 231022152
MAIL ADDRESS:
STREET 1: C/O INTRA-CELLULAR THERAPIES, INC.
STREET 2: 3960 BROADWAY
CITY: NEW YORK
STATE: NY
ZIP: 10032
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Intra-Cellular Therapies, Inc.
CENTRAL INDEX KEY: 0001567514
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 364742850
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 430 EAST 29TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10016
BUSINESS PHONE: 212-923-3344
MAIL ADDRESS:
STREET 1: 430 EAST 29TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10016
FORMER COMPANY:
FORMER CONFORMED NAME: Oneida Resources Corp.
DATE OF NAME CHANGE: 20130122
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-06-14
0
0001567514
Intra-Cellular Therapies, Inc.
ITCI
0001585697
Hineline Lawrence J.
C/O INTRA-CELLULAR THERAPIES, INC.
430 EAST 29TH STREET
NEW YORK
NY
10016
0
1
0
0
SVP of Finance CFO
1
Common Stock
2023-06-14
4
M
0
40472
53.63
A
40472
D
Common Stock
2023-06-14
4
M
0
25082
23.94
A
65554
D
Common Stock
2023-06-14
4
M
0
11762
36.89
A
77316
D
Common Stock
2023-06-14
4
M
0
4538
56.73
A
81854
D
Common Stock
2023-06-14
4
S
0
34227
63.35
D
47627
D
Common Stock
2023-06-14
4
S
0
44035
64.37
D
3592
D
Common Stock
2023-06-14
4
S
0
3592
65.01
D
0
D
Stock Option (right to purchase)
53.63
2023-06-14
4
M
0
40472
0.00
D
2026-01-03
Common Stock
40472
0
D
Stock Option (right to purchase)
23.94
2023-06-14
4
M
0
25082
0.00
D
2030-02-17
Common Stock
25082
0
D
Stock Option (right to purchase)
36.89
2023-06-14
4
M
0
11762
0.00
D
2031-02-22
Common Stock
11762
5882
D
Stock Option (right to purchase)
56.73
2023-06-14
4
M
0
4538
0.00
D
2032-03-09
Common Stock
4538
9078
D
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.795 to $63.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.79 to $64.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.81 to $65.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
All shares underlying this option have vested.
On February 23, 2021, the reporting person was granted options to purchase 17,644 shares of common stock, vesting in three equal annual installments beginning on the first anniversary of the grant date.
On March 10, 2022, the reporting person was granted options to purchase 13,616 shares of common stock, vesting in three equal annual installments beginning on the first anniversary of the grant date.
/s/ Lawrence J. Hineline
2023-06-16